Skip to Main Content

A simmering clash between brand-name and generic drug makers may be reviewed by the US Supreme Court on Friday, and the outcome could determine some key procedural steps for pharmaceutical patent litigation. And this, in turn, might influence just how fast copycat drugs can get to market.

At issue is the legal concept of jurisdiction which, essentially, refers to the location of the court where a lawsuit is heard. And venues can be important, especially since some courts may be better equipped than others to sort out complex challenges to prescription drug patents.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED